M. Arcila

发表

Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

Jae Cheol Lee, Thomas LaFramboise, Chang-Min Choi, 2012, Nature Genetics.

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy

M. Ladanyi, R. Benayed, Soo-Ryum Yang, 2021, Gynecologic oncology reports.

Cancer-testis antigen expression and immunogenicity in AL amyloidosis

D. Seldin, S. Gnjatic, A. Jungbluth, 2012, Blood Cancer Journal.

Title: Effects of co-occurring genomic alterations on outcomes in patients with KRAS mutant non-small cell lung cancer

M. Ladanyi, M. Berger, C. Rudin, 2017 .

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

M. Ladanyi, M. Berger, A. Drilon, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry

A. Drilon, M. Okada, S. Ou, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

N. Socci, A. Viale, M. Ladanyi, 2011, Science Translational Medicine.

Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

M. Ladanyi, A. Hakimi, R. Motzer, 2017, Kidney cancer.

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

Robert M. Vogel, M. Ladanyi, W. Pao, 2016, Science Signaling.

Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.

M. Ladanyi, M. Berger, C. Rudin, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).

M. Ladanyi, W. Pao, J. Teruya-Feldstein, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Application of Machine Learning to the Prediction of Cancer-Associated Venous Thromboembolism

J. Zwicker, G. Soff, M. Arcila, 2023, Research square.

Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI).

M. Ladanyi, M. Kris, W. Pao, 2010 .